University of Tennessee
tennessee.eduMatched: University of Tennessee Medical Center · University of Tennessee Cancer Institute · University of Tennessee
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
178
Active
33
Phase 3
9
Total enrollment
78,371
Pipeline matrix
Showing 14 of 14 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Revefenacin | — | — | — | — | — | 1 | |
| Albuterol Inhalation Aerosol | — | — | — | — | — | 1 | |
| Bupivicaine intervention arm | — | — | — | — | — | 1 | |
| Marcaine hydrochloride without epinephrine 0.5% | — | — | — | — | — | 1 | |
| umeclidinium 62.5 µg and vilanterol 25 µg | — | — | — | — | — | 1 | |
| Revefenacin 175 µg, Formoterol 20 µg | — | — | — | — | — | 1 | |
| Cefiderocol | — | — | — | — | — | 1 | |
| Ketamine | — | — | — | — | — | 1 | |
| 0.9% NaCl | — | — | — | — | — | 1 | |
| Oxycodone | — | — | — | — | — | 1 | |
| Hydromorphone | — | — | — | — | — | 1 | |
| 124I-evuzamitide | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | 2 | ||
| Ropivacaine 0.5% Injectable Solution | — | — | — | — | — | 1 |
Next readouts
- 2023-01-30
- 2025-12
- 2025-12
- 2025-12-01
- 2026-02
- 2027-02-28
- 2027-03
- 2027-12-31
- 2028-05
Top conditions
- Obesity8
- Preeclampsia6
- Pain, Postoperative3
- Cardiovascular Diseases3
- Heart Diseases3
- Hypertension3
- Opioid Use3
- Smoking3
Frequently asked questions about University of Tennessee
- How many clinical trials does University of Tennessee have on ClinicalTrials.gov?
- University of Tennessee is listed as the lead sponsor on 178 clinical trials in ClinicalTrials.gov, 33 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Tennessee's trials are in Phase 3?
- 9 of University of Tennessee's trials are in Phase 3, spread across 14 active drug programs.
- What therapeutic areas does University of Tennessee focus on?
- University of Tennessee's most-studied conditions on ClinicalTrials.gov are Obesity, Preeclampsia, Pain, Postoperative, Cardiovascular Diseases, Heart Diseases.
- When are University of Tennessee's next clinical trial readouts?
- University of Tennessee has 9 upcoming primary-completion readouts tracked here; the soonest is “Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD”, expected around 2023-01-30.